AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
Completed
- Conditions
- GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 312
- Registration Number
- NCT01303692
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 249
- Registration Number
- NCT01300351
- Locations
- 🇨🇳
Research Site, Tianjin, China
Asthma Control Study 2011
Completed
- Conditions
- Asthma Control Level
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1524
- Registration Number
- NCT01298739
- Locations
- 🇭🇺
Research Site, Zalaegerszeg, Hungary
A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT01298310
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 94
- Registration Number
- NCT01297062
- Locations
- 🇺🇸
Research Site, Evansville, Indiana, United States
The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.
Completed
- Conditions
- Essential Hypertension
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1514
- Registration Number
- NCT01295021
- Locations
- 🇮🇳
Research Site, Warangal, India
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
Phase 3
Completed
- Conditions
- Acute Coronary SyndromePercutaneous Coronary Intervention
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 801
- Registration Number
- NCT01294462
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 728
- Registration Number
- NCT01294436
- Locations
- 🇯🇵
Research Site, Toyama, Japan
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Type 2 DiabetesHigh Blood Sugar
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 261
- Registration Number
- NCT01294423
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients
Completed
- Conditions
- Re-bleeding in NVUGIB
- First Posted Date
- 2011-02-10
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1044
- Registration Number
- NCT01292915
- Locations
- 🇻🇳
Research Site, HoChiMinh City, Vietnam